Hear these podcast interviews on the iPad edition of this issue by OT reporters Sarah Maxwell and Peter Goodwin:
AML: Mutant IDH2 Shown as Effective Therapeutic Target
Eytan M. Stein, MD (left), of the Leukemia Service at Memorial Sloan Kettering Cancer Center, reported durable remissions in a Phase I study among patients with IDH2 mutation-positive advanced hematologic malignancies treated with the drug AG-221-an oral, selective, first-in-class inhibitor of the IDH2 mutant metabolic enzyme that also been very well tolerated (Abstract 115). The study is an update from earlier data reported last spring at the AACR Annual Meeting (OT 6/10/14 issue). Also commenting with enthusiastic comments at this stage of the research is David Steensma, MD, of Harvard Medical School and Dana-Farber Cancer Institute, who emphasized the importance of molecular testing for AML patients.
Sorafenib Added to Standard Chemotherapy Benefited Younger Patients with Acute Myeloid Leukemia
Christoph Rollig, MD, of the University of Dresden in Germany, discusses his study showing significantly prolonged event- and relapse-free survival rates in younger patients with AML who had the tyrosine kinase inhibitor sorafenib added to their standard chemotherapy (Abstract 6).
If you are not yet receiving our iPad issues, download the free Oncology Times app from the App Store today! Visithttp://bit.ly/OT-iPadApp, search in the App Store, or follow the link onhttp://oncology-times.com.